Regulus Therapeutics

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell RGLS and other ETFs, options, and stocks.

About RGLS

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development.

CEO

Joseph P. Hagan

CEOJoseph P. Hagan

Employees

Employees26

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

2007

Founded2007

Employees

Employees26

RGLS Key Statistics

Market cap

26.91M

Market cap26.91M

Price-Earnings ratio

—

Price-Earnings ratio—

Dividend yield

—

Dividend yield—

Average volume

54.77K

Average volume54.77K

High today

$1.75

High today$1.75

Low today

$1.55

Low today$1.55

Open price

$1.58

Open price$1.58

Volume

161.65K

Volume161.65K

52 Week high

$3.70

52 Week high$3.70

52 Week low

$1.08

52 Week low$1.08

RGLS Earnings

-$1.00

-$0.67

-$0.33

$0.00

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

— per share

Estimated— per share

Actual

Expected Mar 9, After Hours

ActualExpected Mar 9, After Hours

Regulus Therapeutics

Why Robinhood?

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. Show more

RGLS Key Statistics

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development.